Robert R. Ruffolo to Lead Neuraptive Therapeutics Board

Neuraptive Therapeutics Inc. has appointed industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D., to its Board of Directors.
 
“On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board,” Chairman/CeO Robert Radie said. “His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time. We are fortunate to have attracted such an accomplished leader in our industry which speaks to the promise and potential of the work we are doing to transform the treatment of peripheral nerve injuries.”
 
Ruffolo has more than 40 years of R&D experience and is currently the chairman of Aragen Biosciences Inc. and managing director of Ruffolo Consulting LLC, a consulting company for the pharmaceutical and biotechnology industries. Ruffolo is the retired president of Research and Development of Wyeth Pharmaceuticals, and corporate senior vice president of the Wyeth Corporation (now Pfizer). He managed an R&D organization of 9,000 scientists with an annual budget in excess of $5 billion. Prior to Wyeth, Ruffolo held executive roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Lilly Research Laboratories.

Ruffolo earned his Ph.D. in pharmacology and his bachelor of science degree in pharmacy from The Ohio State University.
 
Neuraptive Therapeutics Inc. develops therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia.